- Teva’s adjusted EBITDA forecast for 2025 is between $4.5 billion and $5 billion, which is below the estimated $5.28 billion.
- Teva expects revenue in the range of $16.8 billion to $17.4 billion, slightly below the estimate of $17 billion.
- Projected free cash flow for Teva is between $1.6 billion and $1.9 billion.
- For the fourth quarter, Teva reported revenue of $4.2 billion, surpassing the estimate of $4.13 billion.
- Austedo’s North American revenue saw significant growth, increasing by 27% year-over-year to $518 million.
- Treanda & Bendeka’s North American revenue decreased by 21% year-over-year to $41 million.
- Copaxone’s North American revenue fell by 13% year-over-year to $63 million.
- Copaxone’s European revenue also saw a decline, down 11% year-over-year to $50 million.
- Teva’s CEO, Mr. Richard Francis, highlighted 2024 as a transformative year with growth driven by generic and key innovative products.
- For 2025, Teva plans to focus on its innovative growth drivers and expand its complex generics and biosimilars business with new product launches.
- The current investment consensus includes 9 buys and 2 holds, with no sell recommendations.
“`
A look at Teva Pharmaceutical Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking ahead for Teva Pharmaceutical Industries, the Smartkarma Smart Scores give us a glimpse into the company’s long-term prospects. With a balanced overall outlook, Teva scores moderately on key factors. While its Value and Dividend scores fall in the mid-range, the company’s Growth and Resilience scores also show a similar trend. On the positive side, Teva’s Momentum score stands out comparatively, indicating a stronger current market performance.
Being a pharmaceutical company with a global reach, Teva Pharmaceutical Industries is positioned to navigate the market with resilience. While the Smart Scores suggest a stable outlook for the company, the overall picture indicates room for improvement in certain areas. Investors may find Teva a steady player in the pharmaceutical sector, with potential for growth and maintaining momentum in the market as it continues to serve customers worldwide with its diverse product portfolio.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
